These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 15827160

  • 1. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
    Zhu M, Bristol JA, Xie Y, Mina M, Ji H, Forry-Schaudies S, Ennist DL.
    J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
    [Abstract] [Full Text] [Related]

  • 2. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL, Ryan P, Gorziglia M, Clarke L, Hawkins LK, Hay C, Huang Y, Kaloss M, Marinov A, Phipps S, Pinkstaff A, Shirley P, Skripchenko Y, Stewart D, Forry-Schaudies S, Hallenbeck PL.
    Cancer Res; 2003 Apr 01; 63(7):1490-9. PubMed ID: 12670895
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo.
    Rivera AA, Wang M, Suzuki K, Uil TG, Krasnykh V, Curiel DT, Nettelbeck DM.
    Virology; 2004 Mar 01; 320(1):121-34. PubMed ID: 15003868
    [Abstract] [Full Text] [Related]

  • 5. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D.
    Gene Ther; 2005 Sep 01; 12(17):1333-46. PubMed ID: 15920462
    [Abstract] [Full Text] [Related]

  • 6. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO.
    Gene Ther; 2006 Jul 01; 13(13):1010-20. PubMed ID: 16525479
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.
    Robinson M, Ge Y, Ko D, Yendluri S, Laflamme G, Hawkins L, Jooss K.
    Cancer Gene Ther; 2008 Jan 01; 15(1):9-17. PubMed ID: 17853920
    [Abstract] [Full Text] [Related]

  • 8. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
    Bortolanza S, Bunuales M, Alzuguren P, Lamas O, Aldabe R, Prieto J, Hernandez-Alcoceba R.
    Cancer Gene Ther; 2009 Sep 01; 16(9):703-12. PubMed ID: 19229289
    [Abstract] [Full Text] [Related]

  • 9. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
    Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, Reddy PS, Yu DC.
    Clin Cancer Res; 2006 Jan 01; 12(1):305-13. PubMed ID: 16397056
    [Abstract] [Full Text] [Related]

  • 10. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.
    Cancer Res; 2001 Sep 01; 61(17):6428-36. PubMed ID: 11522637
    [Abstract] [Full Text] [Related]

  • 11. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.
    Cancer Gene Ther; 2004 Mar 01; 11(3):174-85. PubMed ID: 14726958
    [Abstract] [Full Text] [Related]

  • 12. [Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models].
    Shen FB, Yang C, Lei N, Ju Q, Guo Y, Yi B, Luo ZX, Li HX, Wang L.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun 01; 38(3):386-90. PubMed ID: 17593813
    [Abstract] [Full Text] [Related]

  • 13. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.
    Clin Cancer Res; 2006 Nov 01; 12(21):6523-31. PubMed ID: 17085667
    [Abstract] [Full Text] [Related]

  • 14. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
    Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J, Brooks G, Lemoine N, Kirn D.
    Nat Biotechnol; 2003 Nov 01; 21(11):1328-35. PubMed ID: 14555956
    [Abstract] [Full Text] [Related]

  • 15. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK, Seong YR, Lee YH, Kim MJ, Hwang KS, Yoo J, Choi S, Jung CR, Im DS.
    Mol Ther; 2004 Nov 01; 10(5):938-49. PubMed ID: 15509511
    [Abstract] [Full Text] [Related]

  • 16. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy.
    Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, Sugarman B, Demers GW, Engler H, Johnson D, Shabram P.
    Nat Biotechnol; 2001 Nov 01; 19(11):1035-41. PubMed ID: 11689848
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis.
    Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH.
    Cancer Gene Ther; 2005 Jan 01; 12(1):61-71. PubMed ID: 15375379
    [Abstract] [Full Text] [Related]

  • 19. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
    Li Y, Idamakanti N, Arroyo T, Thorne S, Reid T, Nichols S, VanRoey M, Colbern G, Nguyen N, Tam O, Working P, Yu DC.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8845-55. PubMed ID: 16361574
    [Abstract] [Full Text] [Related]

  • 20. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI, Luo C, Nawa A, Fujimoto Y, Watanabe D, Goshima F, Tsurumi T, Nishiyama Y.
    Cancer Gene Ther; 2007 Nov 15; 14(11):918-26. PubMed ID: 17693992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.